Cogent Biosciences (COGT) Common Equity (2017 - 2026)

Cogent Biosciences (COGT) has 10 years of Common Equity data on file, last reported at $607.7 million in Q1 2026.

• On a quarterly basis, Common Equity rose 177.49% year-over-year to $607.7 million in Q1 2026; TTM through Mar 2026 was $607.7 million, a 177.49% increase from a year earlier, with the FY2025 full-year figure at $636.4 million, up 148.31% from the prior year.
• Common Equity for Q1 2026 stood at $607.7 million, down from $636.4 million in the prior quarter.
• Over the last five years, Common Equity for COGT reached as high as $636.4 million in Q4 2025 and fell as low as $155.0 million in Q2 2025.
• Historically, Common Equity has averaged $321.9 million across 5 years, with a median of $302.5 million in 2025.
• Across the five-year window, Common Equity sank 58.46% in 2025 and soared 177.49% in 2026, its largest moves.
• Year by year, Common Equity stood at $255.7 million in 2022, then grew by 0.81% to $257.8 million in 2023, then declined by 0.59% to $256.3 million in 2024, then jumped by 148.31% to $636.4 million in 2025, then declined by 4.51% to $607.7 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $607.7 million in Q1 2026, $636.4 million in Q4 2025, and $302.5 million in Q3 2025.